University of California, San Francisco - Center for Tobacco Control Research & Education - Postdoctoral Fellowships

The supplemental modified risk tobacco product application for IQOS 3 (s MRTPA) does not adequately address new published research and information on the appeal of IQOS 3 to youth, consumer perceptions of IQOS 3, or the likelihood that the proposed labeling and marketing will mislead consumers, especially youth. The s MRTPA also does not demonstrate benefits to individual or population health. Therefore, FDA should not issue an MRTP order for IQOS 3.

Official source page tracked for University of California, San Francisco - Center for Tobacco Control Research & Education - Postdoctoral Fellowships.